4Garnier J.Rebuilding the R&D engine in big pharma.Harvard Business Review,2008,86(5):68. 被引量：1
5DiMasi J A,Hansen R W,Grabowski H G.The price of innovation:new estimates of drug development costs.J Health Econ,2003,22(2):151-186. 被引量：1
6Trouiller P,Olliaro P,Torreele E,et al.Drug development for neglected diseases:a deficient market and a public-health policy failure.The Lancet,2002,359(9324):2188-2194. 被引量：1
7Bunnage M E.Getting pharmaceutical R&D back on target.Nature Chemical Biology,2011,7(6):335. 被引量：1
